Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
For investors considering whether Roche Holding at around CHF318 represents fair value or a potential opportunity, this article walks through the numbers to show how the current price compares with the company’s fundamentals.
The stock has returned 31.1% over the last year, despite a 6.8% decline over the past 30 days and a year-to-date decline of 2.3%. This combination may have drawn interest from investors who monitor shifts in sentiment and perceived risk.
Recent coverage has highlighted Roche Holding’s role in global pharmaceuticals and ongoing product pipeline developments, which provides context for the share price performance over the past year. Investors are also monitoring how the company addresses competitive pressures and regulatory trends, factors that can influence how they view the current valuation.
Roche Holding currently has a valuation score of 5/6. The next sections compare several valuation approaches and then present a broader framework to help you interpret those methods more effectively.
Find out why Roche Holding’s 31.1% return over the last year is lagging behind its peers.
A Discounted Cash Flow, or DCF, model estimates what a business might be worth today by projecting its future cash flows and discounting them back to a present value.
For Roche Holding, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in CHF. The latest twelve month free cash flow is about CHF 13.6b. Analyst estimates and subsequent extrapolations by Simply Wall St project free cash flow reaching around CHF 20.3b by 2030, with intermediate annual projections between CHF 15.9b and CHF 22.5b over the next decade.
When all those projected cash flows are discounted back, the resulting intrinsic value is CHF 774.18 per share. Compared with the current share price of about CHF 318, the DCF output suggests the shares trade at a 58.9% discount to this estimate, and on this basis the stock screens as undervalued in this model.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Roche Holding is undervalued by 58.9%. Track this in your watchlist or portfolio, or discover 247 more high quality undervalued stocks.
ROP Discounted Cash Flow as at Apr 2026
For profitable companies, the P/E ratio is a useful shorthand for how much you are paying for each unit of earnings, which makes it a practical way to compare businesses that already generate consistent profits.
What counts as a “normal” or “fair” P/E depends on how the market views a company’s growth potential and risk profile. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually point to a lower one.
Roche Holding currently trades on a P/E of about 19.6x. This sits below the Pharmaceuticals industry average of around 21.4x and well below the peer group average of about 43.3x. Simply Wall St’s Fair Ratio for Roche Holding is 37.4x. This reflects a proprietary view of what the P/E could be given factors such as earnings growth characteristics, margins, industry, market cap and risk inputs.
The Fair Ratio aims to be more tailored than a simple comparison with peers or the broad industry, because it blends company specific traits with sector and size considerations. Comparing the Fair Ratio of 37.4x with the current 19.6x P/E suggests the shares screen as undervalued on this metric.
Result: UNDERVALUED
SWX:ROP P/E Ratio as at Apr 2026
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 96 top founder-led companies.
Earlier it was mentioned that there is an even better way to understand valuation. Narratives take the story you believe about Roche Holding, such as how its late stage pipeline, diagnostics rollout, China pricing reforms or US$50b US investment might shape future revenue, earnings and margins, and turn that into a forecast and a fair value. You can then quickly compare that fair value with the current price of about CHF 318 inside Simply Wall St’s Community page, where Narratives are kept up to date as new news or earnings arrive. One investor might align with a more optimistic view closer to CHF 415, while another leans toward a cautious stance nearer CHF 295, and both can see in one place how their story, numbers and valuation connect.
For Roche Holding, we have made it easy for you with previews of two leading Roche Holding Narratives:
These give you a quick feel for what more optimistic and more cautious investors are baking into their numbers, so you can see which story sits closer to your own view before you look at the full details.
🐂 Roche Holding Bull Case
Fair value in this narrative: CHF 352.
Implied pricing gap versus the last close of CHF 318: around 9.7% undervalued.
Revenue growth assumption: about 2.1% a year.
Assumes Roche converts a broad late stage pipeline and up to 19 potential launches into new medicines that help balance loss of exclusivity on older products.
Builds in contribution from targeted therapies and complex diagnostics platforms, with margins supported by AI use, portfolio pruning and efficiency efforts.
Relies on analysts’ consensus view that by 2029, revenue could reach about CHF 67.4b and earnings about CHF 17.2b, with the shares trading on a P/E of roughly 18.3x.
🐻 Roche Holding Bear Case
Fair value in this narrative: CHF 295.
Implied pricing gap versus the last close of CHF 318: around 7.8% overvalued.
Revenue growth assumption: roughly flat over the next few years.
Assumes the large late stage pipeline converts to sales more slowly, with execution risk, competition in obesity and CVRM, and pricing pressure in diagnostics weighing on progress.
Builds in only modest earnings growth, with ongoing loss of exclusivity and policy headwinds partly offsetting benefits from R&D, US$50b of US investment and restructuring.
Aligns with a lower analyst fair value of CHF 295 based on earnings of about CHF 15.8b by 2029 and a P/E of roughly 16.7x, which points to limited upside from the current share price in this scenario.
If you want to see how these stories are built from the ground up, including full catalyst lists, detailed assumptions and complete risk sections, See what the community is saying about Roche Holding.
Do you think there’s more to the story for Roche Holding? Head over to our Community to see what others are saying!
SWX:ROP 1-Year Stock Price Chart
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROP.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com